BIMINI Biotech
Last verified 2026-05-06. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $3.5Mattributed |
|---|---|
| Latest round | seed, $3.2M, 2025-01-01attributed |
| Founded | 2019 |
| Headquarters | Leiden, Netherlands |
| Industry | bio |
| Stage | seed |
| Website | biminibiotech.nl |
Develops first-in-class small-molecule WASp modulators, including agonist BM-011 and antagonist programs. Targets patients with AML, lymphomas, leukemias and autoimmune conditions like arthritis and colitis. Dual agonist-and-antagonist platform unlocks WASp biology, licensed in from Switzerland's Institute of Oncology Research.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-01 | seed | $3.2M | undisclosed |
Detected tech stack
PHP 7.4.33, WordPress 6.5.8, Apache HTTP Server, Mesmerize Companion 1.6.149, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, ExtendThemes Mesmerize, Varnish, MySQL, jquery 3.7.1, apache
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $3.2M | attributed | eu-startups named as publisher. No document URL on file. |
| Total raised $3.5M | attributed | eu-startups named as publisher. No document URL on file. |
| Company existence | self-reported | biminibiotech.nl, read 2026-05-06 |
| Description | self-reported | biminibiotech.nl, read 2026-05-06 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.